Search research articles
Contact Us
Filters
Showing results (71-80 of 96) with videos related to
Page
of 10
Sort By:
Blood
|
March 23, 2010
Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase
Jirí Pavlů, Andrea K Kew, Beatrice Taylor-Roberts, et al.
Blood
|
September 22, 2010
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors
Mustafa Daghistani, David Marin, Jamshid Sorouri Khorashad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2011
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
David Marin, Amr R Ibrahim, Claire Lucas, et al.
Leukemia & Lymphoma
|
November 6, 2012
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop
Richard A Van Etten, Michael Mauro, Jerald P Radich, et al.
Blood
|
September 21, 2007
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia
Eduardo Olavarria, Shamyla Siddique, Michael J Griffiths, et al.
Haematologica
|
October 17, 2009
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Dragana Milojkovic, Emma Nicholson, Jane F Apperley, et al.
Cancer
|
August 19, 2007
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells
Michael W N Deininger, Jorge Cortes, Ron Paquette, et al.
Blood
|
August 4, 2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
Timothy P Hughes, Andreas Hochhaus, Susan Branford, et al.
Blood
|
August 8, 2008
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford, Linda Fletcher, Nicholas C P Cross, et al.
British Journal of Haematology
|
August 16, 2002
The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase
Eduardo Olavarria, Josy Reiffers, Concha Boque, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 96) with videos related to
Sort By:
Page
of 10
Blood
|
March 23, 2010
Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase
Jirí Pavlů, Andrea K Kew, Beatrice Taylor-Roberts, et al.
Blood
|
September 22, 2010
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors
Mustafa Daghistani, David Marin, Jamshid Sorouri Khorashad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2011
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
David Marin, Amr R Ibrahim, Claire Lucas, et al.
Leukemia & Lymphoma
|
November 6, 2012
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop
Richard A Van Etten, Michael Mauro, Jerald P Radich, et al.
Blood
|
September 21, 2007
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia
Eduardo Olavarria, Shamyla Siddique, Michael J Griffiths, et al.
Haematologica
|
October 17, 2009
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Dragana Milojkovic, Emma Nicholson, Jane F Apperley, et al.
Cancer
|
August 19, 2007
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells
Michael W N Deininger, Jorge Cortes, Ron Paquette, et al.
Blood
|
August 4, 2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
Timothy P Hughes, Andreas Hochhaus, Susan Branford, et al.
Blood
|
August 8, 2008
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford, Linda Fletcher, Nicholas C P Cross, et al.
British Journal of Haematology
|
August 16, 2002
The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase
Eduardo Olavarria, Josy Reiffers, Concha Boque, et al.
Page
of 10